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Abstract In clinical practice various modalities are used
for whole-body imaging of the musculoskeletal system,
including radiography, bone scintigraphy, computed tomog-
raphy, magnetic resonance imaging (MRI), and positron
emission tomography-computed tomography (PET-CT).
Multislice CT is far more sensitive than radiographs in the
assessment of trabecular and cortical bone destruction and
allows for evaluation of fracture risk. The introduction of
combined PET-CT scanners has markedly increased diag-
nostic accuracy for the detection of skeletal metastases
compared with PET alone. The unique soft-tissue contrast
of MRI enables for precise assessment of bone marrow
infiltration and adjacent soft tissue structures so that
alterations within the bone marrow may be detected before
osseous destruction becomes apparent in CT or metabolic
changes occur on bone scintigraphy or PET scan. Improve-
ments in hard- and software, including parallel image
acquisition acceleration, have made high resolution whole-
body MRI clinically feasible. Whole-body MRI has
successfully been applied for bone marrow screening of
metastasis and systemic primary bone malignancies, like
multiple myeloma. Furthermore, it has recently been
proposed for the assessment of systemic bone diseases
predisposing for malignancy (e.g., multiple cartilaginous
exostoses) and muscle disease (e.g., muscle dystrophy).
The following article gives an overview on state-of-the-art
whole-body imaging of the musculoskeletal system and
highlights present and potential future applications, espe-
cially in the field of whole-body MRI.
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Introduction
The skeletal system is a frequent target of metastatic spread
from various primary tumors like carcinoma of the breast,
lung and prostate cancer. Moreover, primary malignancies
may also originate from the bone marrow, such as lymphoma
and multiple myeloma [1]. Therefore, it is highly important
to accurately assess manifestations of malignant diseases
within the bone marrow in order to facilitate adequate
therapy and predict prognosis.
Only pronounced destruction of bone with loss of bone
mineral content exceeding 50% is readily visible in radio-
graphic examinations [2]. Computed tomography (CT) is
definitely more sensitive than radiography and it is the image
modality of choice to evaluate the extent of destruction of
trabecular and cortical bone and to assess stability and
fracture risk. Magnetic resonance imaging (MRI), on the
other hand, allows bone marrow components, such as
hematopoietic and fat cells, to be visualized. Moreover,
tumor infiltration into the spinal canal and paravertebral soft
tissues is clearly depicted. Compared with other imaging
modalities like radiography, CTor bone scintigraphy, it is the
most sensitive technique for the detection of pathologies
restricted to the bone marrow, even if trabecular bone is not
destroyed [3, 4]. It has been reported that up to 40% of
skeletal metastases occur outside the field of view covered
by a routine assessment of the axial skeleton, underlining the
importance of whole-body bone marrow imaging [5]. In the
past, different requirements for patient positioning and coil
set-up complicated the introduction of MRI as a practicable
whole-body application. With multi-channel whole-body MRI
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e-mail: Gerwin.Schmidt@med.uni-muenchen.de(WB-MRI) scanners, however, head-to-toe assessment of the
whole skeletal system has become a realistic option without
compromises in image quality compared with dedicated
examinations of limited anatomical areas. Beyond the assess-
mentofmalignantboneneoplasms,WB-MRIhasrecentlybeen
proposed for the whole-body imaging of systemic muscle
disease and may prove useful for an evidence-based screening
of patients suffering from diseases that predispose to bone
malignancy (e.g., multiple cartilaginous exostoses).
Technical aspects of whole-body MRI
Due to its lack of ionizing radiation MRI seems suitable for
whole-body imaging, but for a long time its primary application
has been the assessment of focal pathologies within particular
organsand bodyparts.The most severe challenges ofWB-MRI
in the past have been long examination times, mainly caused by
time-consuming patient repositioning and changing of the array
configuration. Initially, the sequential scanning approach for
WB-MRI of the skeletal system consisted of separate scanning
steps of T1-weighted and STIR (short tau inversion recovery)
imaging at five body levels with at least one patient reposition-
ing process using conventional head, neck, body, and spine
array coils. For a complete whole-body examination, including
dedicated imaging of the spine in sagittal orientation, a total
room time of at least 60 min had to be taken in account.
Steinborn et al. introduced for the first time this whole-body
bone marrow scanning concept for the screening of bone
metastases and, despite the considerable complexity of the
examination, reported advantages in diagnostic accuracy for
MRIcomparedwithconventionalWBimagingtechniques,like
skeletal scintigraphy [6]. Later, attempts to overcome FOV
restrictions and increase patient comfort were based on a
rolling platform concept mounted on top of the scanner table,
making the patient glide in between a “coil sandwich”
comprised of the body coil and the integrated spine coil
(AngioSURF™/BodySURF™; MR-Innovation, Essen, Ger-
many). However, with this approach considerable compro-
mises in spatial resolution, especially in peripheral body
regions like the head/neck and lower extremities, had to be
tolerated [7]. With the introduction of multi-channel MR
scanners, using a system of multiple phased array coils
covering the whole body like a matrix, imaging of the total
skeletal system without compromises in spatial resolution
became possible. In particular, the combination of free table
movement with parallel imaging acquisition techniques (PAT)
resulted in substantially shorter room time and allowed to
integrate otherwise time-consuming, but indispensable se-
quence types for bone marrow imaging (e.g., STIR sequen-
ces). The proposed imaging protocol for high resolution
T1-weighted turbo spin echo (TSE) and STIR imaging from
head to toe is performed with 1.3×1.1-mm and 1.8×1.3-mm
plane resolution respectively (5-mm slices, matrix 384, PAT
2–3). Additionally, dedicated T1-weighted TSE and STIR
imaging of the complete spine is performed (1.0×1.0-mm
plane, 3-mm slices, matrix 384), which results in a total scan
time of 43 min.
A promising new concept for WB-MRI is the continu-
ously moving table technique with the use of PAT. Recently,
a SENSE reconstruction algorithm has been successfully
applied on stationary receiver coils with arbitrary coil
dimensions for continuously 3D gradient echo imaging of
the complete body without significant constraints in image
quality [8]. Zenge et al. have reported promising initial
results for 3D whole-body continuous data acquisition
using the rolling table concept as a new potential strategy
for WB-MRI metastases screening, especially for large
field-of-view imaging in short bore systems [9].
Technical aspects of whole-body CT
Multislice CT (MS-CT) is frequently used in oncologic
imaging, and in the detection of bone destruction CT is far
more sensitive than radiography [10]. Moreover, it is unique in
its ability to evaluate the extent of osseous destruction and to
assess stability and fracture risk [11]. Whole-body imaging
usually implies CT of the neck, thorax, abdomen/pelvis in
axial orientation with multi-planar reconstructions and recal-
culation of bone window setting. Continuous hardware
improvements for CT imaging from single-slice scanners to
64-slice scanners have resulted in larger FOV and faster
acquisition times with high resolution. Examination time now
i sr e d u c e dt o1 –2 min and improvement in resolution with the
resulting formation of isotropic voxels allows high quality
multiplanar reconstructions. In particular, the use of ultrathin
collimation (0,5 mm) can provide excellent image quality for
the neck and peripheral skeleton. Furthermore, with automated
tube current dose modulation systems exposure of the patient
to ionizing radiation could be reduced by 10–68% on average,
depending on the anatomical region, without substantially
sacrificing image quality [12]. Absolute dose reduction
(described as volume CT dose index) ranges from 11.97/
8.18 mGy for a pelvic examination to 23.28/7.45 mGy when a
combined angular and z-axis modulation system is used.
Multislice CT enables bone destruction to be detected as
well as osteoblastic and mixed patterns with osteosclerosis
and destruction. In cases of diffuse bone marrow infiltration
inhomogeneousosteoporosismaybedetected.However,asin
radiography, this may mimic osteoporosis, unless areas of
bony destruction are present. 3D reconstruction algorithms,
like VRT (volume rendering technique), can be used to
display complex fractures (e.g., pathological fracture) and
further increases the reliability to detect occult vertebral
fractures compared with plain radiographs. Furthermore, the
1110 Skeletal Radiol (2007) 36:1109–11193D morphology of vertebral fractures may give indications
concerning the nature of the fracture (e.g., tumorous vs.
osteoporotic fracture).
Clinical application of whole-body MRI
W h o l e - b o d yM R Ii si n c r e a s i n g l yu s e di nt h ef i e l do f
oncologic imaging as an adjunct or alternative to established
multi-modality approaches (e.g., radiographs, MS-CT, ultra-
sound, scintigraphy)forinitial tumor staging orscreeningfor
tumor recurrence after curative therapy. Promising results
have been reported for the detection of distant metastatic
disease, especially in tumors that frequently metastasize to
the bone, liver, and brain (Fig. 1)[ 13, 31]. Recently, WB-
MRI has been proposed as a sensible application for a more
integrated assessment of multiple myeloma and systemic
muscle diseases [16, 17, 18, 19].
Metastasis
Based on morphological criteria in radiography, CT, and MRI,
skeletal metastases are classified as osteolytic (approximately
50%), osteoblastic (35%) ,and mixed type (15%). For MRI
bone screening, the combination of unenhanced T1-weighted
spin echo and turbo-STIR sequences proved to be highly
sensitive in discriminating benign from malignant marrow
disorders [20]. On T1-weighted sequences tumor spread is
identified by replacement of normal fat containing marrow,
resulting in a hypointense signal . Fat-suppressed sequences,
such as STIR, depict neoplastic lesions by virtue of the
hyperintense signal due to increased content of water within
the tumor cells (Fig. 2). However, osteoblastic metastases may
be depicted in STIR sequences with variable signal intensities
from hypointense in dense sclerotic lesions to hyperintense
when more cellular components are present [21]. The unique
soft-tissue contrast of MRI allows precise assessment of tumor
infiltration within the bone marrow and even diffuse
infiltration of the bone marrow with neoplastic cells, not
associated with focal bone destructions or formation of new
bone, is detected [22]. In some cases additional sequences,
such as dynamic studies of signal enhancement after
gadolinium injection, may be performed for accurate differ-
entiation from benign bone marrow changes, such as
hyperplastic bone marrow formation [23]. Finally, MRI allows
for precise assessment of adjacent paraosseous structures, such
as the spinal canal.
Whole-body MRI compared with bone scintigraphy
In clinical practice multi-modality algorithms are most com-
monly used when metastatic bone disease is suspected. They
include radiography, bone scintigraphy, PET, CT, and MRI. In
many institutions
99mTc-phosphonate-based bone scanning is
performed as the method of initial bone marrow screening.
However, scintigraphy provides only limited spatial resolution
and at an early stage of disease lesions may remain invisible in
the absence of an osteoblastic response [24]. Furthermore,
misinterpretation of tracer uptake in healing fractures or
degenerative disease may lead to false-positive findings. The
diagnostic performance of MRI compared with bone scintig-
raphy for the detection of skeletal metastases has been
examined in various studies and higher specificity and
sensitivity in the early detection of skeletal metastases have
been reported [6, 24, 25]. Steinborn et al. compared combined
T1-weighted and STIR WB-MRI with bone scintigraphy
using the sequential scanning approach in a lesion-by-lesion
analysis [6]. WB-MRI reliably detected more confirmed
skeletal metastases (91%) than bone scintigraphy (85%).
Another study group reported higher sensitivity and specificity
of WB-MRI (92%/90%) compared with scintigraphy (83%/
80%) on a patient-by-patient basis [20]. Daldrup-Link et al.
analyzed both methods for the detection of bone metastases in
39 children and young adults and observed a higher sensitivity
of 82% for WB-MRI compared with 71% for scintigraphy,
with this difference increasing, especially in medium-sized
lesions between 1 and 5 cm [3].
Interestingly, both methods showed differences in perfor-
mance according to lesion location. Most false-negatives in
scintigraphy were found in the spine, while diagnostic
problems for WB-MRI occur in the thoracic cage and skull,
especially when coronal imaging orientation is used, a problem
that is certainly increased by motion artefacts. These problems
might be overcome when using fast turbo spin echo sequences
forthoracicimagingincombinationwithaxialsliceorientation.
Whole-body MRI compared with MS-CT
Multislice CT is far more sensitive than radiography in the
assessment of focal bone destructions. Krahe et al. compared
radiography and CT examinations in 112 patients with
metastases of the spine [10]. MS-CT identified 268 involved
vertebrae while radiography depicted 88% of these lesions
when the vertebral body was involved and only 66% when
other parts of the vertebrae were affected. Intraspinal and
paravertebral tumor extension was correctly assessed by
plain radiography in only 23% and 33% of cases respec-
tively. Recently, multidetector MS-CT has been proposed for
whole-body screening of the skeletal system as an alternative
to bone scintigraphy [26]. Groves et al. investigated 43
patients with suspected bone metastases using bone scintig-
raphy and 16-detector MS-CT and detected metastatic
disease in 14 out of 43 and 13 out of 43 patients respectively,
with an agreement of 84%, suggesting a similar diagnostic
performance of both modalities. The authors concluded that
in case of suspected skeletal metastasis, scintigraphic studies
Skeletal Radiol (2007) 36:1109–1119 1111may not be needed, when an adequate whole-body MS-CT
tumor staging with recalculation of bone window setting has
been performed. Consecutively, this might shorten diagnostic
pathways and save resources. However, it is not yet clear
whether MS-CT is equal to MRI for the assessment of bony
metastases. First results have demonstrated the superior
detection rate of MRI (Fig. 1)[ 27].
Whole-body MRI compared with PET-CT
In contrast to MRI and MS-CT, positron emission tomog-
raphy (PET) using [18F]-fluorodeoxyglucose (FDG) pro-
vides functional information by tracing increased FDG
uptake directly into the tumor cells. Recent studies indicate
that whole-body FDG-PET increases specificity of bone
Fig. 1 A 60-year-old patient with a malignant melanoma. a Coronal
T1-weighted turbo spin echo (TSE) whole-body (WB) magnetic
resonance imaging (MRI) indicates multifocal metastatic disease of
the liver (arrow). b Whole-body positron emission tomography-
computed tomography (PET-CT) shows multiple areas of pathologic
[18F]-fluorodeoxyglucose (FDG)-uptake in the right atrium (arrow),
the liver (arrowheads), and in the right iliac bone (arrowhead). c
Contrast-enhanced CT reveals a metastasis within the right atrium. d
T1-weightedTSEWB-MRIconfirmsahypointenselesionintherightiliac
bone indicating bone metastasis. e Axial fat-saturated contrast-enhanced
MRI of the pelvis shows another bone metastasis in the right sacral bone
(arrow). f, g The corresponding CT images in the bone window setting
show extensive osteolysis within the right iliac bone; however, no
morphologic changes are found in the right sacral bone
1112 Skeletal Radiol (2007) 36:1109–1119screening compared with bone scintigraphy, although there
is conflicting evidence whether there is a significant gain in
sensitivity [28]. Still, FDG is a tracer that is not tumor-
specific and may also accumulate in the presence of
inflammation and thus lead to false-positive findings. Also,
FDG is not suitable for several tumor entities due to poor
tracer uptake, e.g., prostate cancer, myxoid tumors of the
gastrointestinal tract, low-grade sarcomas or renal cell
carcinomas [29]. A clear technical disadvantage of PET,
similar to scintigraphy, is its poor anatomical resolution,
which often makes the exact localization of a lesion
difficult. Fused PET-CT scanners combine the functional
data of PET with the detailed anatomical information of
MS-CT scanners in a single examination and have further
improved diagnostic accuracy. Various authors have
reported a significant decrease in ambiguous lesions and
an improvement in the specificity of PET-CT compared to
that of PET alone in the detection of malignant disease [14,
30].
Only a few study groups have directly compared the
performance of WB-MRI with FDG-PET-CT in the detection
of skeletal metastases [15, 31]. Antoch et al. analyzed the
accuracy of both modalities in 98 patients in terms of TNM-
based tumor staging. Both imaging procedures revealed a
similar diagnostic sensitivity to the detection of distant
metastases (WB-MRI93%, PET-CT 94%). Regarding bone
metastases, the sensitivity was significantly higher when
using WB-MRI (85%) instead of PET-CT (62%). Our own
observations confirm these data. We examined 41 patients
with suspected skeletal metastases with both FDG-PET-CT
and WB-MRI using a multi-channel scanner with PAT [31].
In a lesion-by-lesion analysis 102 malignant and 25 benign
bone lesions were confirmed by histology or follow-up. WB-
MRI showed a significantly higher diagnostic accuracy than
PET-CT (91% vs. 78%, Figs. 1, 2). In particular, lesions
smaller than 5 mm were visualized by WB-MRI with a cut-
off size of 2 mm for WB-MRI compared with 5 mm for
PET-CT. Lesions less than double the size of the spatial
Fig. 2 A 28-year-old man with non-Hodgkin’s lymphoma. a Coronal
whole-body STIR imaging shows suspect areas with hyperintense
signal in the right clavicular region and both iliac bones. b
Magnification shows a mass extending from the right clavicular fossa
and infiltrating the right apical thoracic cage. c The lesion shows a
pathological FDG uptake in PET-CT, indicating malignancy. d The
T1-weighted sagittal image of the spine shows extensive multifocal
lymphoma manifestations. e PET-CT underestimates the degree of
tumor involvement by showing tracer uptake only in the thoraco-
lumbar region
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lead to false-negative results. Additionally, 10 bone metastases
indistalpartsofthebodywererevealedbyWB-MRIduetothe
larger field of view (the FOVof a routine PET-CT is restricted
to the diagnostic spiral CT, usually ranging from the skull base
to the proximal femora). However, specificity was higher in
PET-CT (PET-CT 80% vs.WB-MRI 76%). Here,certainly,the
additional metabolic information of PET plays the most
important role in reliably discriminating between malignant
and benign lesions (e.g., atypical haemangioma) [32].
On the other hand, at least in breast cancer, different
patterns of FDG uptake have been reported in osteoblastic,
osteolytic or mixed lesions, indicating that sclerotic lesions
may be less FDG-avid [33]. The additional morphologic
information of PET/CT compared with PET alone is
certainly of great value in increasing diagnostic sensitivity.
Also, significant improvement in diagnostic accuracy has
been reported when 18F-fluoride is used for PET or PET-
CT for the assessment of malignant skeletal disease. 18F-
fluoride is a tracer that, similar to
99mTC-diphosphonate,
specifically adsorbs onto bony surfaces with a predilection
for sites of active bone formation [30].
An important indication in bone imaging is lesion
monitoring after chemotherapy or radiation therapy. It has
to be taken into account that on MRI necrotic bone
metastases may remain virtually unchanged in morphology
Fig. 3 A 70-year-old man with multiple myeloma. a The radiograph of
the pelvis is inconspicuous. b Coronal MS-CT reconstruction of the
pelvis in a bone window setting reveals a large area of destruction within
the left iliac bone (arrow). c) STIR-WB-MRI confirms focal tumor
manifestation within the iliac bone (arrow) and reveals multiple small
nodular infiltrations within the sacral bone and pelvis. d MS-CT of the
spine shows a compression fracture of Th9. e, f T1-weighted SE- and
STIR imaging of the spine reveals diffuse myeloma infiltration of the
spine. g Coronal STIR sequences of the pelvis show additional focal
infiltration of the left femoral head missed on radiography and MS-CT
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therapy response difficult. Compared with viable tumors, the
contrast enhancement is frequently less pronounced and
slower in tumors that have responded to a particular therapy.
Reductionintumorsizemaybedelayedandisnotasensitive
sign in the assessment of response. Tumor metabolism, and
consequently FDG uptake, is highly susceptible to chemo-
therapy. On the CT image, osteolytic metastases often
demonstrate typical sclerotic transformation. In this setting,
future studies are needed to evaluate the sensitivity of FDG-
PET-CT in assessing the response to chemotherapy and
whether sensitivity is reduced in the first days after initiation
of therapy. After radiation therapy MRI is particularly
helpful, because irradiated lesions are easily distinguishable
from new lesions because of the high signal of normal bone
marrow on T1-weighted SE images, which is due to
conversion of hematopoietic into fatty bone marrow.
Multiple myeloma
Multiple myeloma is a frequent neoplastic disease affecting
the bone marrow. It is characterized by expansive growth of
malignant plasma cell clones with consecutive destruction of
the bony architecture. Predilection sites are the axial skeleton
(spine and pelvis), but also the ribs, the shoulder region,
skull, and proximal femurs, stressing the need for total body
imaging for adequate assessment of the extent of disease.
The bone marrow may either be diffusely infiltrated or there
may be focal accumulations of atypical plasma cells (Fig. 3).
In patients with myeloma the basic diagnostic work-up in
many institutions includes radiographic examinations of the
skull (two planes), the rib cage, the upper arms, the spine
(two planes), the pelvis, and the upper legs. This diagnostic
approach is still represented in the classic Salmon and Durie
staging system of the disease, which includes radiographic,
immunohistochemical, and serological factors of the disease,
and defines the selection of adequate therapy [34]. However,
diagnostic sensitivity of radiography in the detection of
myeloma manifestations is rather low and thus allows
diagnosis only at advanced stages of the disease when at
least 50% of the bone mineral content has been lost [2]. In
particular, a diffuse bone marrow infiltration pattern may
cause diagnostic problems as it can easily be misdiagnosed
as senile osteoporosis. In a study conducted by Baur et al.
55% of focal and 59% of diffuse infiltrations were missed
by radiography [35]. With the use of contrast-enhanced
sequences and calculation of percentage signal increases the
sensitivity of MRI for diffuse myeloma infiltration, espe-
cially at earlier stages, can be further increased [36].
Schreiman et al. examined 32 patients with multiple
myeloma using single-row CTand radiography [37]. Twelve
patients showed osseous affections in both modalities. CT,
however, usually demonstrated a more extensive involve-
ment and in 6 out of 13 patients only CT detected myeloma
involvement despite normal radiographs. Another study
group recently proposed FDG-PET-CT as an alternative to
radiographic imaging of the whole body [38]. PET-CT
detected more lesions in 16 out of 28 patients (57%) and 9 of
these patients had completely negative radiography.
Ghanem et al. compared WB-STIR-MRI using the
conventional radiographic skeletal survey in 54 patients
with plasma cell neoplasms [16]. Whole-body MRI
correctly revealed bone marrow infiltration in 74% of
patients, while radiography depicted pathological changes
in 55% of patients. Moreover, WB-MRI showed a larger
extent of infiltration in 90% of concordant findings.
In two studies, the diagnostic accuracy of MS-CT and
MRI was analyzed. Mahnken et al. compared results of
four-detector MS-CT and MRI examination of the spine
and pelvis in 18 patients with stage III multiple myeloma
[39]. A total number of 325 vertebral bodies were
evaluated. In MS-CT 231 vertebral bodies were classified
as “affected”, compared with only 224 vertebral bodies in
MRI. These “false-negative” findings might have been a
consequence of response to previous treatment. However, no
informationaboutprevioustherapywasprovidedinthisstudy.
On the other hand, MRIshowed5 affectedvertebrae that were
considered normal on MS-CT. The false-negatives on MS-CT
mightbeduetoearlybonemarrowinfiltrationwithoutsignsof
osseous destruction. Furthermore, the surprisingly high
sensitivity of MS-CT in this study may also be caused by
pre-selection of a patient group with advanced disease.
In our own study, 30 patients with multiple myeloma were
examined with a 1.5-Tesla multi-channel WB-MRI scanner
and a 16- and 64-detector MS-CTscanner [17]. MRI showed
superior diagnostic accuracy to MS-CT. In particular, the
diagnostic sensitivity of MS-CT was inferior to that of WB-
MRI (Fig. 3). The high amount of false-negatives on MS-CT
may be explained by the fact that early stages of the disease
can be visualized on MRI, displaying bone marrow
replacement before any destruction of trabecular and cortical
bone occurs. False-positive results on MS-CT, on the other
hand, may be due to misinterpretation of inhomogeneous
osteoporosis as diffuse myeloma infiltration.
Baur et al. were able to show that an extended staging
system, including MRI of the spine, has a significant
influence on the assessment of prognosis. Using the classic
staging system of Durie and Salmon without MRI, 25 out of
77 patients would have been understaged, thus underlining
the importance of incorporating the MRI bone marrow status
into staging and therapy planning of this disease [40].
Muscle disease
Diagnostic imaging of muscle disease (e.g., polymyositis or
muscle dystrophy) represents a challenge as it requires
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tures to adequately assess the pattern, distribution, and
extent of the disease. CT, scintigraphy, and ultrasound are
not suitable for this purpose as all these modalities lack
sufficient soft tissue contrast, spatial resolution or large
FOV imaging options. Other diagnostic tests frequently
used, like electromyography, are unspecific and muscle
biopsies used as the gold standard have been reported to be
false-negative in 10–25% of cases due to sampling errors
[41]. MRI, with its precise delineation of fat, muscle, and
bone is an ideal candidate for imaging of systemic muscle
disease. Moreover, substantial dose exposure in a predom-
inantly younger patient cohort commonly affected by
muscle diseases can be avoided. Previously, MRI has been
used for a targeted assessment of muscle disease [41, 42]. A
combination of T1-weighted SE and T2-weighted pulse
sequences with fat saturation, such as STIR, are indispens-
able for assessing increased fat and water content within the
muscle tissue respectively (Fig. 4). Contrast enhancement
with Gadolinium chelates also adds to diagnostic accuracy,
especially when combined with fat suppression. Since
various muscle groups and body parts may be involved in
an unpredictable distribution, coverage of the whole body is
important.
Fig. 4 a Whole-body MRI of a 60-year-old man suffering from
severe progressive muscle dystrophy, symmetrically affecting the
muscles of the rib cage, abdomen, pelvis, and lower extremities. b
WB-STIR shows signs of diffuse reactive edematous processes in the
left upper thighs and muscles of the distal lower limbs. c, d T1-
weighted imaging displays fatty tissue replacement affecting most of
the muscles of the pelvis. Residual adductor muscle tissue is shown
with high contrast due to its hypointense signal. e Progressive muscle
dystrophy has also occurred in the lower extremities, affecting all
compartments
1116 Skeletal Radiol (2007) 36:1109–1119O’Connell et al. previously described WB-STIR imaging
for the diagnosis of patients suffering from polymyositis
[18]. With the use of parallel imaging techniques WB-STIR
imaging can be performed in under 13 min at an inplane
resolution of 1.3×1.1 mm. With this method, symmetry of
muscle involvement and the extent and severity of
inflammation can be analyzed, so that an adequate target
for biopsy can be identified. During therapy, WB-MRI is
particularly helpful in monitoring the disease outcome by
visualizing the muscle-to-fat tissue relation or to verify a
decrease in inflammation. Also, various drugs, such as
steroids, may have side effects that involve the muscles and
result in various types of myopathy. Lenk et al. proposed
coronal and axial WB-STIR imaging in combination with
coronal T1-weighted SE imaging and sagittal T1-/T2-
weighted imaging of the spine, as a sensible protocol for
systemic muscle disease, resulting in an approximate total
scan time of 45 min [19].
However, assessment of distal parts of the upper
extremity may be limited. This is due to positioning of
the arms on the pelvis and thighs. If the muscles of the
forearm are in the focus of interest, additional examination
with dedicated coil systems may be required.
Patients with muscular dystrophy, an X-chromosome
recessive disease, suffer from progressive destruction of
muscle tissue with subsequent replacement by fatty and
Fig. 5 A 35-year-old man with multiple cartilaginous exostoses. a, b
Whole-body MRI shows typical manifestations in the metaphyseal
parts of the long bones of the upper and lower extremities. c
Enlargement of the left knee joint shows an exostosis at the medial
side of the femur and at the proximal tibia. d Deformation of the
radius. e Exostoses and deformation of both femoral necks. In
summary, no indications of malignant transformation (e.g., widening
of the cartilaginous cap) were found in this patient
Skeletal Radiol (2007) 36:1109–1119 1117fibrous tissue. In addition to the morphological information
concerning the distribution and extent of replacement of
muscle by fatty tissue as provided by WB-MRI, exact
quantification of the muscle-to-fat relation is of substantial
diagnostic and prognostic importance. In particular, T1-
weighted axial WB-MRI in combination with CAD
(computer aided diagnostics) applications may be useful
for the quantification of total body fat distribution.
Interesting results have been reported by Brennan et al.
who introduced a fast, automated approach to body fat
measurement in healthy individuals as a useful alternative
to the body mass index [43].
Future applications
Eustace et al. have proposed WB-MRI for trauma assess-
ment in patients referred for suspected child abuse [44]. For
a rapid assessment of acute trauma, especially when
multiple organs are affected, MS-CT provides fast and
detailed systemic information on potentially life-threatening
organ, vessel or bone injury and is the imaging technique of
choice. Recently, an accelerated triage MS-CT protocol has
been proposed by Koerner et al. for time-effective handling
of mass casualty incidents using MS-CT. For a scenario of
15 multiple trauma patients admitted over a period of 2 h
within a mass casualty incident a mean total time in the
scanner room of 8.9 min was calculated, including patient
preparation and image reconstruction [45].
Finally, there may be potential for WB-MRI in the sec-
ondary screening of congenital skeletal diseases predispos-
ing to malignancies, like multiple cartilaginous exostoses
or histiocytosis X (Fig. 5). However, only case reports have
been published on the potential benefits or therapeutic
impact in these specific patient groups.
Conclusion
Whole-body imaging is increasingly successfully applied in
musculoskeletal imaging, especially in the field of systemic
malignant diseases affecting the bone and in diseases
predisposing to malignant transformation. Whole-body MRI
isabletodepictbonemarrowpathologieswithhighresolution
and excellent soft tissue contrast by demonstrating signal
alterations due to changes in its fat, water, and hematopoietic
cell components with high resolution and excellent soft tissue
contrast. Together with CT or PET-CT and its valuable
additional metabolic information, it has great potential in the
more comprehensive, more accurate, and earlier diagnosis of
musculoskeletal diseases. Although further evaluation of the
true potential of whole-body applications is awaited, they are
promising tools aiding the more efficient management of
patients suffering from systemic malignant or benign diseases
of the soft tissue and bone.
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